BioAtla (BCAB) Cash & Equivalents (2020 - 2026)

BioAtla's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 93.94% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $2.0 million, a 93.94% decrease from a year earlier, with the FY2025 full-year figure at $7.1 million, down 85.49% from the prior year.
• Cash & Equivalents fell to $2.0 million in Q1 2026 per BCAB's latest filing, from $7.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $219.4 million in Q1 2022 and bottomed at $2.0 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $71.1 million (2024), against an average of $95.6 million.
• Across the five-year window, Cash & Equivalents dropped 0.8% in 2022 and sank 93.94% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $178.1 million in 2022, then tumbled by 37.42% to $111.5 million in 2023, then sank by 56.0% to $49.0 million in 2024, then tumbled by 85.49% to $7.1 million in 2025, then slumped by 72.45% to $2.0 million in 2026.
• Per Business Quant, the three latest BCAB Cash & Equivalents figures stand at $2.0 million (Q1 2026), $7.1 million (Q4 2025), and $8.3 million (Q3 2025).